Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 8,003 matching trials from the live ClinicalTrials.gov search.
Conditions
Head and Neck Squamous Cell Cancer
Interventions
INO-3112, CELLECTRA™-5P
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers Results available

Atrial Fibrillation Algorithms Clinical Validation Study

NCT04699812
Conditions
Atrial Fibrillation
Interventions
ELECTROCARDIOGRAM (ECG) PATCH WEAR
Device
Lead sponsor
Apple Inc.
Industry
Eligibility
22 Years and older
Enrollment
573 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Coral Gables, Florida • Avon, Indiana • Wichita, Kansas + 1 more
Conditions
Relapsed Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Interventions
Pembrolizumab, Lenalidomide
Biological · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York
Conditions
Advanced Cancer
Interventions
FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
19
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
Conditions
Pulmonary Embolism, Pulmonary Embolism Subacute Massive
Interventions
inhaled nitric oxide (iNO)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Active, not recruiting Phase 1Phase 2 Interventional

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Interventions
MDNA11, Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Medicenna Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Santa Monica, California + 4 more
Conditions
Head and Neck Neoplasms
Interventions
M4N
Drug
Lead sponsor
Erimos Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Resectable Esophageal Cancer, GastroEsophageal Cancer
Interventions
Avelumab combined with Chemoradiation, Carboplatin, Paclitaxel, Radiation
Combination Product · Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Terminated Phase 1Phase 2 Interventional Results available

AB1 in Adult Patients With Sickle Cell Disease (SCD)

NCT05261711
Conditions
Sickle Cell Disease
Interventions
AB1
Drug
Lead sponsor
Nirmish Shah
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Augusta, Georgia • Durham, North Carolina • Greenville, North Carolina
Conditions
Microsatellite Stable Colorectal Cancer
Interventions
grapiprant, grapiprant and pembrolizumab
Drug
Lead sponsor
Arrys Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Aurora, Colorado • Nashville, Tennessee + 1 more
Conditions
NSCLC
Interventions
EP0031, Platinum chemotherapy, Pemetrexed
Drug
Lead sponsor
Ellipses Pharma
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 16 more
Conditions
Alcohol Associated Hepatitis
Interventions
INT-787, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Fresno, California • Palo Alto, California • Sacramento, California + 17 more
Conditions
Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Interventions
Urelumab (BMS-663513)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • Chicago, Illinois + 9 more
Conditions
Pancreatic Cancer
Interventions
Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine, Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine, Part A- VS-4718, nab-paclitaxel, gemcitabine
Drug
Lead sponsor
Verastem, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
St Louis, Missouri • Gettysburg, Pennsylvania
Conditions
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
Interventions
ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more
Conditions
Multiple Myeloma
Interventions
Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
34
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 21 more
Conditions
Multiple Sclerosis
Interventions
Ofatumumab 3mg, Ofatumumab 30mg, Ofatumumab 60mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
16
States / cities
Cullman, Alabama • Fullerton, California • Fairfield, Connecticut + 13 more
Conditions
Type 2 Diabetes Mellitus
Interventions
sotagliflozin (SAR439954), midazolam, metoprolol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Leukemia, Myeloid, Acute
Interventions
Bleximenib, Venetoclax (VEN), Azacitidine (AZA), Cytarabine, Daunorubicin or Idarubicin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 4 more
Conditions
Glenohumeral Arthritis, Rotator Cuff Arthropathy
Interventions
intraarticular corticosteroid injection (IACI), suprascapular nerve block (SSNB)
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Cranioplasty, Craniofacial Abnormalities, Craniofacial Injuries
Interventions
Stryker's PEEK Customized Implant
Device
Lead sponsor
Stryker Craniomaxillofacial
Industry
Eligibility
42 Months and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Louisville, Kentucky • New Brunswick, New Jersey • New York, New York + 2 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of SPY002-072 in Healthy Volunteers

NCT06622070
Conditions
Healthy
Interventions
SPY002-072, Placebo
Drug · Other
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cypress, California
Conditions
Cachexia
Interventions
GSK2881078, Placebo, Itraconazole
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Lymphoma, Non-Hodgkin, Hodgkin Disease
Interventions
SD-101, Local Radiation
Drug · Radiation
Lead sponsor
Robert Lowsky
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Palo Alto, California